The patentUS5709704involved in this suit is currentlyassigned[i]to Boston Scientific SciMed Inc. (source: Maxval’sAssignment Database). The patent entitled Blood clot filtering was issued on January 20, 1998 and expires[ii] on January 20, 2015. According to the complaint, plaintiff is the owner with rights to enforce and prosecute actions for infringement of the ‘704 patent.
About the Parties:
LifeScreen Sciences LLC has a place of business in Frisco, TX.
Cordis Corporationdevelops products to treat circulatory system diseases including congestive heart failure and cerebral aneurysms. Cordis is divided into five units: Cordis Cardiology focuses on cardiovascular disease diagnosis and treatment, Cordis Endovascular develops devices for endovascular and liver diseases, Biosense Webster develops medical sensor and electrophysiology technology for cardiovascular use, Conor Medsystems provides vascular drug delivery technologies and the Biologics Delivery Systems division makes cardiac mapping equipment used to improve the delivery of biological therapies. The company was founded in 1959 and operates as a subsidiary of Johnson & Johnson.
As in Complaint:
Plaintiff alleges that defendant manufactures and markets TrapEase®and OptEase®Retrieval Vena Cava Filtersthat infringe the methods claimed in the ‘704 patent. TrapEase Permanent Vena Cava Filter (see Fig.1) is indicated for use in the prevention of recurrent pulmonary embolism (PE) via percutaneous placement in the inferior vena cava. OptEase® Retrievable Vena Cava Filter (see Fig. 2) is the same as TrapEase Filter plus the additional option of retrieval.
If you are interested in knowing in detail about the case filed byLifeScreen Sciences, pleasecontact us.